Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)

ClinicalTrials.gov ID: NCT00492284

Public ClinicalTrials.gov record NCT00492284. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne®-Lucentis® Combination Therapies and Lucentis® Monotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to AMD.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis \[within 2 hours\] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple therapy \[within 2 hours\]) reduces retreatment rates compared with Lucentis monotherapy while maintaining similar vision outcomes and an acceptable safety profile.

Study identification

NCT ID: NCT00492284
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: QLT Inc.; Industry
Enrollment: 162 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 50 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2007
Primary completion: Apr 30, 2009
Completion: Apr 30, 2010
Last update posted: Jun 1, 2011

2007 – 2010

United States locations

U.S. sites: 21
U.S. states: 13
U.S. cities: 21

Facility	City	State	ZIP	Site status
Not listed	Mobile	Alabama	—	—
Not listed	Phoenix	Arizona	—	—
Retina Centers, PC	Tucson	Arizona	—	—
Not listed	Beverly Hills	California	—	—
Not listed	Campbell	California	—	—
Not listed	Los Angeles	California	—	—
Not listed	Poway	California	—	—
Not listed	Sacramento	California	—	—
Not listed	Torrance	California	—	—
Not listed	Fort Myers	Florida	—	—
Not listed	Indianapolis	Indiana	—	—
Not listed	Davenport	Iowa	—	—
Not listed	Missoula	Montana	—	—
Not listed	Omaha	Nebraska	—	—
Not listed	Portsmouth	New Hampshire	—	—
Not listed	Portland	Oregon	—	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	West Mifflin	Pennsylvania	—	—
Not listed	Arlington	Texas	—	—
Not listed	Temple	Texas	—	—
Not listed	Seattle	Washington	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00492284, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 1, 2011 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00492284 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →